Genelux (NASDAQ:GNLX) Downgraded by Wall Street Zen to Sell

Genelux (NASDAQ:GNLX - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research report issued to clients and investors on Friday.

A number of other equities research analysts have also weighed in on GNLX. HC Wainwright restated a "buy" rating and set a $30.00 price objective on shares of Genelux in a research report on Monday, March 31st. Benchmark cut their target price on Genelux from $25.00 to $23.00 and set a "speculative buy" rating on the stock in a report on Thursday, May 8th. One investment analyst has rated the stock with a sell rating, four have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $17.75.

Genelux Price Performance

GNLX stock traded up $0.03 during midday trading on Friday, reaching $2.56. 128,852 shares of the stock were exchanged, compared to its average volume of 189,487. The stock has a market capitalization of $96.60 million, a PE ratio of -2.69 and a beta of -0.49. Genelux has a 52 week low of $1.60 and a 52 week high of $5.89. The company has a fifty day moving average price of $2.55 and a 200 day moving average price of $3.06.

Genelux (NASDAQ:GNLX - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.21) earnings per share for the quarter, topping analysts' consensus estimates of ($0.24) by $0.03. As a group, analysts anticipate that Genelux will post -0.88 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Apollon Wealth Management LLC lifted its holdings in Genelux by 20.4% during the 4th quarter. Apollon Wealth Management LLC now owns 16,863 shares of the company's stock worth $40,000 after buying an additional 2,857 shares during the period. D.A. Davidson & CO. acquired a new position in shares of Genelux in the 4th quarter valued at about $51,000. LPL Financial LLC lifted its stake in shares of Genelux by 72.3% in the 4th quarter. LPL Financial LLC now owns 94,144 shares of the company's stock valued at $222,000 after purchasing an additional 39,516 shares during the period. Raymond James Financial Inc. acquired a new position in shares of Genelux in the 4th quarter valued at about $41,000. Finally, Marshall Wace LLP lifted its stake in shares of Genelux by 51.4% in the 4th quarter. Marshall Wace LLP now owns 156,058 shares of the company's stock valued at $368,000 after purchasing an additional 52,958 shares during the period. 37.33% of the stock is owned by institutional investors and hedge funds.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.